Puma Biotechnology : Corporate Presentation

Puma Biotechnology

June 2024

Forward-LookingSafe-Harbor Statement

This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications

and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ

materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.

Product Pipeline

			Phase I		Phase II		Phase III	Registration	Approval
Neratinib: Tyrosine kinase inhibitor	N
HER2+ Breast Cancer
	Extended adjuvant				ExteNET	(Phase III HER2+	EBC*)
	Neratinib monotherapy		CONTROL
	Metastatic				NALA (Phase	III 3rd Line HER2+	MBC**)
	Monotherapy or combo therapy
	Metastatic w/ brain mets		TBCRC-022 (T-DM1 + neratinib)
	Monotherapy or combo therapy
Alisertib: Aurora kinase A inhibitor		NSABP FB-7
			TBCRC-041 (fulvestrant + alisertib)
HRc+*** HER2-negative MBC						Initiation in	Q4'24
			ALISCA-Breast1 (alisertib+endocrine)
Metastatic EGFR-mutant NSCLC****	NCT04085315 (alisertib+osimertinib)
Small cell lung cancer		ALISCA-Lung1 (PUMA-ALI-4201)		Initiated in Q1'24
			8						*
	Copyright 2024 Puma Biotechnology	* ECB: Early breast cancer	** MBC: Metastatic breast cancer	*** HRc+: Hormone receptor positive ****NSCLC: Non small cell lung cancer	3

Puma's Pharmacy and Distributor Network

Hub Services

Specialty Pharmacy Network (SP)

Acaria Health	Accredo
CVS	ONCO 360
Optum /	Patients
Biologics
Diplomat

Sites of Care

Specialty Distributor Network (SD)

Academic Hospitals

McKesson

Community Hospitals

ASD/Oncology Supply

Physician Practices

Cardinal Health

Others (VA, DOD)

DMS Pharmaceutical Group

Inc.

Copyright 2024 Puma Biotechnology

4

$40.3 Million Net NERLYNX Revenue in Q1'24

~14% decline in Q1'24 compared to Q1'23

Net Revenue (in $MM)

46.8
	40.3
Q1'2023	Q1'2024

Inventory Change ($)

Q1'2023	Q1'2024
-$3.8 mil	-$2.0 mil

~24% decrease Q1'24 compared to Q4'23

Net Revenue (in $MM)

53.2
	40.3
Q4'2023	Q1'2024

Inventory Change ($)

Q4'2023	Q1'2024
+$2.1 mil	-$2.0 mil

Copyright 2024 Puma Biotechnology

5

2,410 Ex-Factory Bottles Were Sold in Q1'24

~15% decline in Q1'24 compared to Q1'23

	Bottles
2,849
	2,410
Q1'2023	Q1'2024

Inventory Change Bottles

Q1'2023	Q1'2024
-236	-120

~16% decline in Q1'24 compared to Q4'23

	Bottles
2,881
	2,410
Q4'2023	Q1'2024

Inventory Change Bottles

Q4'2023	Q1'2024
+127	-120

Copyright 2024 Puma Biotechnology

6

~67% of Patients in Q1'24 Started at a Reduced Dose*

% of Patients Starting at Reduced Dose

			76.4%
		67.9%	69.5% 71.2%
	65.4%	66.7%
		64.0% 64.0%
59.4% 61.5%

54.9%

42.4%

37.7% 38.7%

28.0% 30.0% 31.0% 32.8%

19.0%

12.0% 11.0%

2.0% 2.0% 3.0% 4.0% 6.0% 7.0%

*Reduced dose defined as fewer than 6 pills per day

Copyright 2024 Puma Biotechnology

7

Rest of World Partnerships - Timelines

Region	Partner			Regulatory Approvals			Commercial Launches
	• 2019 - Ext. Adj. in Australia, Singapore
Australia / SE Asia	•	2020	- Ext. Adj. in Brunei, Malaysia, New Zealand	•	2020 - Singapore
•	2022	- Ext. Adj. in the Philippines; mBC in Singapore	•	2021 - Malaysia, Brunei, New Zealand
	• 2023 - mBC in Malaysia
Israel	•	2020	-	Approved in Ext. Adj. and mBC	•	2020	- Launched
Canada	• 2019 - Ext. Adj. approved	•	2020	- Launched
•	2021 - mBC approved
	•	2019	-	Ext Adj in Argentina
	•	2020	-	Ext. Adj in Chile, Ecuador; mBC in Argentina	•	2020 - Argentina
	• 2021 - Ext Adj. and mBC in Peru; mBC in Chile; Ext.
	• 2021 - Chile and Peru
Latin America		Adj. in Brazil
	•	2022	- Brazil
	• 2022 - Ext. Adj. in Mexico; mBC in Ecuador
	• Q1 2023 - Mexico and Colombia
	• 2023 - mBC in Colombia and Mexico
Europe					•	2019	- Germany, UK, Austria
Greater China	•	2019 - Ext. Adj. EMA and Hong Kong	• 2020 - Sweden, Finland, Scotland, Switzerland, Denmark,
	and Hong Kong
Middle East	•	2020	- Ext. Adj. in China, Taiwan
•	2021	- China (added to 2021 NRDL), Taiwan, Greece,
North and West Africa	•	2021	- mBC in Taiwan
	Czech Republic, and Luxembourg
South Africa	• 2023 - Ext. Adj. in Morocco, South Africa, and UAE
•	2022	- Ireland and Spain
• Q1 2024 - Ext. Adj. Syria
Turkey	•	2023	- Slovakia
					•	Q1 2024 - Morocco
South Korea	•	2021	- Ext. Adj. in S. Korea	•	2022	- Launched

Copyright 2024 Puma Biotechnology

8

NERLYNX® Extended Adjuvant HER2+ Breast Cancer Market Size

Approximately 28,300 patients (US) with early stage HER2+ breast cancer treated with adjuvant treatment1

Approximately 6,000 patients (US) with HR positive early stage HER2+ breast cancer and no pathological complete response to neoadjuvant treatment (high risk disease)

Approximately 37,000 patients (EU) with early stage HER2+ breast cancer treated with adjuvant treatment1

• Approximately 65-70% of patients have HR positive disease

1Roche epidemiology slides 09/18

Copyright 2024 Puma Biotechnology

9

Puma Financial Guidance for Q2 and FY 2024

	Q2 2024	Full Year 2024
NERLYNX revenue guidance:	$38 - 40 million	$183 - 190 million
NERLYNX royalty guidance:	$2.5 - 3 million	$30 - 34 million
NERLYNX license revenue:	$0 million	$1	- 2 million
Net income (loss):	$(6) - (9) million	$12	- 15 million
Gross to net adjustment:	22 - 23%	21.5 - 22.5%

Copyright 2024 Puma Biotechnology

10